Zydus Cadila approaches DCGI to use hepatitis drug for COVID-19 clinical trial

New Delhi [India], May 5 (ANI): The country's top drug regulator, Drug Controller General of India (DCGI), has received an application from Zydus Cadila, the leading global pharmaceutical company in India, to conduct clinical trial using antiviral drug 'Pegylated Interferon Alpha-2b' in adult COVID-19 patients.

from ANI News: Lifestyle News, Health Tips, Life and Latest Trends on Fashion
Read The Rest:aninews...